13th Annual GEICAM Review of Advances in Breast Cancer
GEICAM started this initiative in 2008 with the purpose of presenting an in-depth review of the most relevant milestones presented at congresses and international publications annually. At this annual multidisciplinary meeting, attended by all professional involved with breast cancer, a comprehensive review of the advances made in research, diagnosis and treatment in connection with this disease has been carried out. The main goal of this event is to become a reference for everyone interested in finding out more about the advances made in terms of breast cancer in an independent, comprehensive and critical fashion. Sign up at: https://www.ragmageicam.org/ and participate!
Save the date for ESMO Highlights Webinar LATAM 2020
Register for ESMO Highlights Webinar LATAM 2020 here: https://www.esmohighlightswebinar2020.com An excellent opportunity for oncologists in Latin America to update their knowledge, a few days after the ESMO2020 Virtual Congress, based on updated scientific evidence. A Scientific Committee with 8 international experts will meet virtually on 9/26/2020 to discuss the progress presented at the ESMO 2020 Virtual Congress, with selections in Genitourinary, Gastrointestinal, Lung, Melanoma, Head and Neck and Breast Cancer, with the objective of disseminating scientific and clinical advances and their impact on the daily clinical practices in Latin America. The event will take place in a virtual environment, under the leadership of Dr. Antonio C. Buzaid and Dr. Carlos H. Barrios, with simultaneous translation in Portuguese and Spanish.
The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)
Members of LACOG Breast cancer group have recently published the article “The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)” AMAZONA III/ GBECAM 0115 is a prospective cohort study that evaluated Brazilian patients with newly diagnosed breast cancer from 2016 to 2018. This manuscript depicts a wide and detailed scenario of sociodemographic characteristics of 2,950 breast cancer patients at diagnosis. The patients were from 23 sites in Brazil. The results of the study show that patients with public health coverage were diagnosed with symptomatic disease, at later stages and with more aggressive subtypes of breast cancer when compared to patients with private health coverage. This study brings to light important information that allows us to not only have a better understanding of tumor and patients’ characteristics but also, help to identify gaps within healthcare systems in Brazil. With such knowledge, it’s possible to develop strategies to improve screening and educational programs in the country, especially in the public setting.
The Best of ASCO 2020 Brazil Edition took place between the 8th and 11th of june 2020
2,731 participants from 26 brazilian states and also from other countries, watched, during 4 days, the virtual scientific program. The event was attended by renowned speakers that presented the main studies of ASCO 2020 on different research fields (Genitourinary, Melanoma/Sarcoma, Gastrointestinal, Hematologic, Breast, Gynecological, Lung, Head and Neck and Neuro), in addition to discussing the perspective of clinical practice. We thank all the attendees, speakers, supporters and sponsors for having been a part of this great event. The Best of ASCO 2020 Brazil Edition, organized by LACOG and Ética Institute, is an event officially licensed by ASCO, which organizes the most important oncology congress in the world with a commitment to accelerating progress against cancer, even in the face of a global pandemic.
GBCP and LACOG Head and Neck Group new members of the Head and Neck Cancer International Group
It is with great pleasure that we inform that GBCP and LACOG Head and Neck Group are now members of the Head and Neck Cancer International Group.
The CURA Project launched a crowdfunding campaign to support research against head and neck cancer
The CURA Project, of which we are supporters, launched a crowdfunding campaign to support research against head and neck cancer. Join us by supporting the campaign to fund 1,000 laboratory tests and contribute to scientific research. We invite you to join together in this great challenge of raising funds to clinical cancer research community. Access The CURA Project website and learn more! Access The Cura Project website
Assistance to cancer patients was dramatically compromised during the covid-19 pandemic, which will result in an increased risk of mortality by approximately 20%.
"A multidisciplinary group with 40 representatives from 35 collaborative groups and medical associations developed a consensus practice recommendations for the continuity of care for patients with head and neck cancer during the pandemic, stressing the importance of not interrupting their treatment, treating patients with established protocols, encouraging distance consultations, and adopting protective measures for patients and staff." - Dr. Prof. Luiz P. Kowalski, Vice-chair LACOG Head and Neck Group and A.C. Camargo Center Oncologist Read more on The Lancet website
LACOG 2019 Annual Report – Download now!
It is with great pleasure that we present the first edition of the LACOG Annual Report, which highlights the most important activities of our group during the year of 2019. Check the 2019 annual report
Memo inOncology Special Issue ASCO 2020 Lung Cancer report
Although the COVID-19 pandemic has prevented on-site attendance at this year’s ASCO meeting (May 29th – May 31st), the global oncology community presented a large range of relevant and potentially practice-changing findings. Highlights of this report include the progress made with regard to various aberrations like ALK, MET, HER2 and RET alterations, as well as EGFR exon 20 insertions and promising drugs in this difficult-to-treat subtype. Moreover, topics including (neo)adjuvant approaches for early stage NSCLC, future perspectives of anti-angiogenic therapy and COVID-19 in the context of thoracic cancer care are covered. Furthermore, the importance of immune checkpoint inhibitors and the determination of unequivocally active combinations of immune agents are addressed. Last but not least, advances in the field of SCLC treatment are presented, valuing immunotherapy in addition to platinum-based chemotherapy, thus bearing a possible new standard-of-care treatment for first-line ES-SCLC. As an additional feature, you will find expert video interviews with Victor Moreno and Helmut Prosch on different conference highlights on memo inOncology website. The memo inOncology Special Issue report is produced by Springer, as a supplement of memo (the Magazine of European Medical Oncology) and sponsored by Boehringer Ingelheim with an unrestricted educational grant. For more information on the memo inOncology
CURA Recognition Award
This month was handed to AMO Clinic (located in Salvador, Brazil) the CURA Recognition Award. AMO is the first institution to receive it, as they have supported CURA since 2015. Learn about CURA Project and get in contact to know how you can effectively be part of CURA Partners. Picture: Dr. Alex Pimenta (Medical Director) and Dr. Carlos Sampaio (president of the administrative council).